...
首页> 外文期刊>Indian heart journal >24 h and 30 day outcome of Perclose Proglide suture mediated vascular closure device: An Indian experience
【24h】

24 h and 30 day outcome of Perclose Proglide suture mediated vascular closure device: An Indian experience

机译:24小时和30天的Perclose Proglide Suture介导的血管闭合装置:印度经验

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Advantages of vascular closure device over manual compression include patient comfort, early mobilisation and discharge, avoidance of interruption of anticoagulation, avoidance of local compression and its sequelae and less time constraint on staff. No published Indian data exist regarding Perclose Proglide suture mediated vascular closure device (SMC). Aim: To study the 24 h and 30 day outcome of Perclose Proglide SMC retrospectively. Study design: Retrospective observational study conducted in the Department of Cardiology, Government Medical College, Calicut, Kerala from June 2013 to June 2015. Methodology: All consecutive patients with Perclose Proglide SMC deployment done by a single operator for achieving access site haemostasis where 24 h and 30 day post-procedure data were available were included. Major and minor complications, procedure success, device failure were predefined. Results: 323 patients were analysed. Procedure success rate was 99.7% (322/323). Transient oozing occurred in 44 patients (13.6%), minor and major complications occurred in 2% and 1.5% of patients respectively. Major complication included one case of retroperitoneal bleed, one access site infection, one pseudo aneurysm formation and two access site arterial stenosis. There was no death or complication requiring limb amputation. "Preclose" technique was used successfully in six patients. Primary device failure occurred in 12 cases which were tackled successfully with second Proglide in all except one. Conclusion: Perclose Proglide SMC is a safe and effective method to achieve haemostasis up to 22F with less complication rate.
机译:介绍:血管闭合装置通过手动压缩的优点包括患者的舒适性,早期动员和放电,避免抗凝中断,避免局部压缩及其后遗程和较少的工作人员限制。没有出版的印度数据存在关于Perclose ProOglide Suture介导的血管闭合装置(SMC)。目的:回顾性地研究普拉罗斯普鲁布利SMC的24小时和30天。研究设计:2013年6月至2015年6月,喀拉拉邦的心脏病学,政府医学院,喀拉拉邦的心脏病学系进行了回顾性观察研究。方法论:单个运营商完成了单次运营商的Perclose Proglide SMC部署的所有连续患者,用于实现24小时的接入站点血统提供了30天的过程后数据。主要和次要的并发症,程序成功,设备故障被预定义。结果:分析323例患者。程序成功率为99.7%(322/323)。瞬态渗透发生在44名患者(13.6%),轻微和主要并发症中分别发生在2%和1.5%的患者中。主要并发症包括一个腹膜后渗流,一种接入部位感染,一个伪动脉瘤形成和两个接入位点动脉狭窄。没有死亡或并发症需要肢体截肢。在六名患者中成功使用“Preclose”技术。在除了一个外,12例初级设备故障发生在12例中,其中包含第二个Proglide。结论:Perclose ProOglide SMC是一种安全有效的方法,可实现血糖,其含量高达22倍,并发症率较小。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号